Arcus Biosciences RCUS EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Arcus Biosciences’s reported figures.
Based on trailing twelve months.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's EBITDA margin?
- Arcus Biosciences (RCUS) reported EBITDA margin of -164.8% in Q1 2026.
- How has Arcus Biosciences's EBITDA margin changed year-over-year?
- Arcus Biosciences's EBITDA margin increased by 45.4% year-over-year, from -302.1% to -164.8%.
- What is the long-term trend for Arcus Biosciences's EBITDA margin?
- Over 5 years (2020 to 2025), Arcus Biosciences's EBITDA margin has grown at a -0.4% compound annual growth rate (CAGR), from -155.1% to -152.2%.
- What does EBITDA margin mean?
- EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.